Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Warts 1 Thyroid Cancer, Papillary 1 Papillomavirus Infections 1 Pancreatic Neoplasms 1 Pancreatic Cyst 1 Neoplasms, Cystic, Mucinous, and Serous 1 Neoplasms 1 Lymphoma 1 Leukemia 1 Hematologic Diseases 1 Epidermodysplasia Verruciformis 1 Condylomata Acuminata 1 Breast Neoplasms 1 Alcohol Drinking 1

Interventions

Trastuzumab 243 Paclitaxel 193 Cyclophosphamide 158 Docetaxel 134 Letrozole 113 Capecitabine 113 Fulvestrant 106 Doxorubicin 103 Bevacizumab 87 Carboplatin 81 exemestane 80 Anastrozole 79 Lapatinib 70 Tamoxifen 69 Albumin-Bound Paclitaxel 57 palbociclib 54 pertuzumab 53 Taxes 51 Gemcitabine 50 Radiotherapy 46 eribulin 43 pembrolizumab 41 Everolimus 41 Ado-Trastuzumab Emtansine 41 Vinorelbine 38 130-nm albumin-bound paclitaxel 35 ixabepilone 32 Epirubicin 28 pegfilgrastim 25 liposomal doxorubicin 25

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Breast Neoplasms × Ethanol × Clear all

NCT01698918 2023-05-03

BOLERO-4

Novartis

Phase 2 Completed

202 enrolled 19 charts

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡